All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-11-01T12:17:05.000Z

ESH 2019 | What are the new concepts to target cancer stem cells in AML?

Featured
Nov 1, 2019
Share:

Bookmark this article

The AML Global Portal were delighted to speak to Ravi Majeti, Stanford University School of Medicine, Stanford, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Ravi Majeti: What are the new concepts to target cancer stem cells in AML?

Ravi Majeti discusses different targets for therapies in AML. These include the self-renewal signaling pathways (e.g. Hedgehog and Wnt) and immunological approaches (e.g. targeting cell surface receptors like CD123 with chimeric antigen receptor [CAR] T-cell therapy). He also raises questions regarding the role of measurable residual disease (MRD).

What are the new concepts to target cancer stem cells in AML?

More about...

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox